Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,601
datasets available to search
ShareScore release 0.9.0
Dataset results
1,601 results for “Prognosis;”
Data from: Baseline C-reactive protein level and life prognosis in Parkinson disease
Background: C-reactive protein (CRP) is a biomarker of inflammation, and high levels of CRP correlate with vascular death. Chronic inflammation is considered to be involved in neurodegeneration, although there is no evidence linking it with the process of neurodegenerative diseases. Objective: To determine the role of baseline CRP levels in the prognosis of patients with Parkinson disease (PD). Methods: A cohort of 313 patients with a mean age of 69.1 and mean PD duration of 7.9 years was retrospectively followed for a mean observation time of 1,753 days. CRP was measured when patients were not diagnosed with any infections, and levels were repetitively measured to investigate a tendency of "regression to mean." The primary outcome measure was a survival time from study enrollment to death. Results: During the observation period 56 patients died. Baseline CRP was log-linearly associated with a risk of death in PD. Mean survival time was 3,149 (95% confidence interval; 3,009-3,289) days in patients with CRP ≤ 0.8mg/L (lower two thirds) and 2,620 (2,343-2,897) days in those with CRP > 0.8 mg/L (top third, p < 0.001, log-rank test). The adjusted hazard ratio (HR) per two-fold higher CRP concentration for all deaths was 1.29 (1.10-1.52), and after excluding PD-unrelated deaths, such as cancer or stroke, HR was 1.23 (1.01-1.49) (adjusted for age, sex, PD duration, modified Hohen-Yahr stages, MMSE scores, and serum albumin). Conclusions: Baseline CRP concentrations were associated with the risk of death and predicted life prognosis of patients with PD. The associations were independent from PD duration, PD severity, cognitive function, ages, and nutritional conditions, suggesting the possibility that subclinical chronic inflammation is associated with a neurodegenerative process in PD.
Data from: Prognosis of chronic kidney disease with normal-range proteinuria: The CKD-ROUTE study
Background: Although lower estimated glomerular filtration rate (eGFR) and higher proteinuria are high risks for mortality and kidney outcomes, the prognosis of chronic kidney disease (CKD) in patients with normal-range proteinuria remains unclear. Methods: In this prospective cohort study, 1138 newly visiting stage G2-G5 CKD patients were stratified into normal-range and abnormal-range proteinuria groups. Study endpoints were CKD progression (>50% eGFR loss or initiation of dialysis), cardiovascular events, and all-cause death. Results: In total, 927 patients who were followed for >6 months were included in the analysis. The mean age was 67 years, and 70.2% were male. During a median follow-up of 35 months, CKD progression, cardiovascular events, and mortality were observed in 223, 110, and 55 patients, respectively. Patients with normal-range proteinuria had a significantly lower risk for CKD progression (hazard ratio, 0.20; 95% confidence interval, 0.10-0.38) than those with abnormal-proteinuria by multivariate Cox proportional hazard analysis. We also analyzed patients with normal-range proteinuria (n=351). Nephrosclerosis was the most frequent cause of CKD among all patients with normal-range proteinuria (59.7%). During a median follow-up of 36 months, CKD progression, cardiovascular events, and mortality were observed in 10, 28, and 18 patients, respectively. The Kaplan-Meyer analysis demonstrated that the risks of CKD progression and cardiovascular events were not significantly different among CKD stages, whereas the risk of death was significantly higher in patients with advanced-stage CKD. Multivariate Cox proportional hazard analysis showed that the risk of three endpoints did not significantly differ among CKD stages. Conclusion: Newly visiting CKD patients with normal-range proteinuria, who tend to be overlooked during health checkups did not exhibit a decrease in kidney function even in advanced CKD stages under specialized nephrology care.
Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with poor prognosis_Spatial H&E images
<p>High-resolution H&E images of spatial transcriptome data</p>
Study of the Incidence and Prognosis of Intrahospital Acute Kidney Injury
ClinicalTrials.gov study NCT06697730. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
The Prognosis Effect of Indocyanine Green (ICG) Fluorescence Guided Surgery on Disease-free Survival (DFS) of Stage III Colorectal Cancer
ClinicalTrials.gov study NCT06583564. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prospective Cohort Study on Prognosis of Patients With Hepatitis B/C
ClinicalTrials.gov study NCT05102838. IPD Sharing: Not stated. Countries: 0. Publications: 0.
The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis
ClinicalTrials.gov study NCT00728871. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy
ClinicalTrials.gov study NCT03830788. IPD Sharing: NO. Countries: 1. Publications: 0.
The Association of Sleep and Psychological Symptoms With Prognosis of MSK Pain in Danish General Practice
ClinicalTrials.gov study NCT03726138. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
ClinicalTrials.gov study NCT05950087. IPD Sharing: NO. Countries: 1. Publications: 0.
Biomarkers for the Early Diagnosis, Prediction, Prognosis for Colorectal Cancers
ClinicalTrials.gov study NCT01828918. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
ClinicalTrials.gov study NCT06771960. IPD Sharing: NO. Countries: 1. Publications: 0.
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study
ClinicalTrials.gov study NCT03744741. IPD Sharing: NO. Countries: 2. Publications: 0.
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
ClinicalTrials.gov study NCT04948437. IPD Sharing: NO. Countries: 1. Publications: 0.
A Cohort of Molecular Characteristics and Prognosis of Colorectal Cancer
ClinicalTrials.gov study NCT05086601. IPD Sharing: NO. Countries: 1. Publications: 0.
UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease
ClinicalTrials.gov study NCT05812612. IPD Sharing: YES. Countries: 1. Publications: 0.
Predictive Model for Prognosis of Chronic HBV Infection Mothers
ClinicalTrials.gov study NCT04805034. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock
ClinicalTrials.gov study NCT07354568. IPD Sharing: NO. Countries: 1. Publications: 0.
Efficacy and Prognosis of Surgical Intervention in Patients With Carotid Artery Stenosis
ClinicalTrials.gov study NCT06222983. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Influence of Beliefs on the Prognosis of Chronic Musculoskeletal Pain.
ClinicalTrials.gov study NCT03036553. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.